Cargando…

P110: CLINICAL CHARACTERISTICS OF COVID-19 IN SICKLE CELL DISEASE (SCD) PATIENTS

Detalles Bibliográficos
Autores principales:	Malhan, H, Iqbal, B, Ghazwani, Y, AlHakim, A, Ali, S, Omar, H, Dammag, E, Khalifah, H, Alqurbi, A, Ekpenyong, U, Subahi, N, Alqahiry, W, Bakkar, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Poster Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812133/ http://dx.doi.org/10.1097/01.HS9.0000821532.87170.d7

Ejemplares similares

P-004: HEALTH CARE TRANSITION (HCT) FOR SICKLE CELL DISEASE (SCD) CAN BE STANDARDIZED: RESULTS OF IMPLEMENTING A SCD HCT LEARNING COLLABORATIVE.
por: I., OSUNKWO, et al.
Publicado: (2022)

P-010: TREATMENTS FOR SICKLE CELL DISEASE (SCD) AND THE HEALTHCARE PROFESSIONAL (HCP)–PATIENT RELATIONSHIP: HCP OPINIONS FROM THE INTERNATIONAL SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY)
por: B., ANDEMARIAM, et al.
Publicado: (2022)

P-042: POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS ANALYSIS OF HYDROXYUREA, IN ADULT PATIENTS WITH SICKLE CELL DISEASE (SCD) RECEIVING BOTH TABLETS OR CAPSULES FORMULATIONS, AND EVALUATION OF DISEASE MARKERS
por: P., BARTOLUCCI, et al.
Publicado: (2022)

P-017: POINT-OF-CARE DIAGNOSTIC FOR QUANTIFICATION OF FOETAL HAEMOGLOBIN (HB F) LEVELS IN MONITORING HYDROXYUREA THERAPY FOR CHILDREN WITH SICKLE CELL DISEASE (SCD) IN GHANA
por: C., SEGBEFIA, et al.
Publicado: (2022)

P1480: SPLENIC SEQUESTRATION IS MORE COMMON IN SCD-S/Β0-THAL THAN IN SCD-S/S PATIENTS: RESULTS FROM THE GERMAN SCD REGISTRY
por: Allard, P., et al.
Publicado: (2022)

Soluble haemoglobin scavenger receptor (sCD163): a marker associated with bacteraemia
por: Gaïni, S, et al.
Publicado: (2005)

Adult T-cell leukemia/lymphoma following elevation of serum levels of soluble cytokine receptors, sCD25 and sCD30
por: Takemoto, Shigeki, et al.
Publicado: (2014)

P103: THE ABNORMAL PRESENCE OF MITOCHONDRIA IN CIRCULATING SCD RED BLOOD CELLS ASSOCIATED WITH STRESS ERYTHROPOIESIS
por: Ramasamy, J, et al.
Publicado: (2022)

5610823 TRIAL IN PROGRESS: THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 1B CROSSWALK-A TRIAL EVALUATING THE SAFETY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE UNCOMPLICATED VASO-OCCLUSIVE EPISODES (VOES) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD)
por: Bartolucci, P., et al.
Publicado: (2023)

P119: TRIAL IN PROGRESS: THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 1B CROSSWALK-A TRIAL EVALUATING THE SAFETY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE UNCOMPLICATED VASO-OCCLUSIVE EPISODES (VOES) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD)
por: Bartolucci, P, et al.
Publicado: (2022)

MR-Augmented Cardiopulmonary Exercise Testing- a proof of concept in Sickle Cell Disease (SCD)
por: Ako, Emmanuel O, et al.
Publicado: (2016)

5613386 CELEBRATING THE SICKLE CELL DISEASE WORLD DAY ON JUNE 19TH AFTER TWO YEARS OF PANDEMIC: MY LIFE WITH SCD, PATIENTS’ PERSPECTIVE
por: Maran, J.E.M., et al.
Publicado: (2023)

5613426 LOW CHRONIC INFLAMMATION IN SCD
por: Rolli, M.R., et al.
Publicado: (2023)

P1497: BURDEN OF SICKLE CELL DISEASE: RESULTS FROM THE REAL WORLD ASSESSMENT SURVEY FOR SICKLE CELL DISEASE IN SAUDI (ROARS)
por: Jastaniah, W., et al.
Publicado: (2022)

Procalcitonin, IL-10 and sCD25 as diagnostic and prognostic markers in critically ill patients
por: Focà, A, et al.
Publicado: (2012)

P1467: HEALTHCARE PROFESSIONALS (HCP) OPINIONS ON TREATMENTS FOR SICKLE CELL DISEASE (SCD) AND THE HCP–PATIENT RELATIONSHIP: RESULTS FROM THE INTERNATIONAL SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY)
por: Andemariam, B., et al.
Publicado: (2022)

5613004 NEWBORN SCREENING FOR SICKLE CELL DISEASE IN GERMANY - THE FIRST YEAR
por: Lobitz, S., et al.
Publicado: (2023)

5612539 TRIAL IN PROGRESS: THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2A CROSSWALK-C TRIAL EVALUATING THE EFFICACY OF CROVALIMAB AS ADJUNCT TREATMENT IN THE PREVENTION OF VASO-OCCLUSIVE EPISODES (VOES) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD)
por: Callaghan, M., et al.
Publicado: (2023)

P-030: CRIZANLIZUMAB REDUCES ENDOTHELIAL ADHESION OF RED BLOOD CELLS FROM SCD PATIENTS IN STANDARDIZED MICROFLUIDIC PLATFORM: IN VITRO TECHNOLOGY ASSESSMENT
por: C., FEDERICI, et al.
Publicado: (2022)

S131: REGIONAL ASSESSMENT OF THE EXPERIENCES OF HEALTHCARE PROFESSIONALS (HCPS) TREATING PATIENTS WITH SICKLE CELL DISEASE (SCD): THE INTERNATIONAL SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY)
por: Osunkwo, I, et al.
Publicado: (2022)

P120: TRIAL IN PROGRESS: THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2A CROSSWALK-C TRIAL EVALUATING THE EFFICACY OF CROVALIMAB AS ADJUNCT TREATMENT IN THE PREVENTION OF VASO-OCCLUSIVE EPISODES (VOES) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD)
por: Callaghan, M, et al.
Publicado: (2022)

The new sepsis marker, sCD14-ST, induction mechanism in the rabbit sepsis models
por: Shirakawa, K, et al.
Publicado: (2010)

P-005: COMPARISON OF SICKLE SCAN AND HEMOTYPE SC AS POINT-OF-CARE NEWBORN SCREENING DIAGNOSTICS FOR SICKLE CELL DISEASE IN LUANDA, ANGOLA
por: B., SANTOS, et al.
Publicado: (2022)

S108: A SYSTEMATIC POST-MARKETING (PM) REVIEW OF RARE INFUSION-RELATED REACTIONS (IRRS) PRESENTING AS PAIN EVENTS DURING OR AFTER CRIZANLIZUMAB INFUSION IN PATIENTS WITH SICKLE CELL DISEASE (SCD)
por: Kanter, J, et al.
Publicado: (2022)

5596911 RETINAL AND MACULAR AFFECTION IN EGYPTIAN SICKLE CELL DISEASE PATIENTS USING SPECTRAL DOMAIN OCT AND OCT-ANGIOGRAPHY: A SINGLE CENTER STUDY
por: El-Ghamrawy, M., et al.
Publicado: (2023)

5613480 REAL WORLD APPLICATIONS OF CLINICAL WHOLE BLOOD ADHESION (VCAM AND P-SELECTIN) BIOMARKERS IN A PEDIATRIC SCD POPULATION
por: Martin, O.Y., et al.
Publicado: (2023)

P110: Influence of signal coloured hand disinfectant dispensers on compliance at an intensive care unit
por: Scheithauer, S, et al.
Publicado: (2013)

P-006: SICKLE RED BLOOD CELL (RBC)-DERIVED EXTRACELLULAR VESICLES ACTIVATE ENDOTHELIAL CELLS AND ENHANCE SICKLE RBC ADHESION MEDIATED BY VON WILLEBRAND FACTOR
por: R., AN, et al.
Publicado: (2022)

Physicians’ and nurses’ perceptions and attitudes toward sickle cell disease patients in Jazan, Saudi Arabia
por: Hazzazi, Ahmad A., et al.
Publicado: (2020)

S110: ACUTE AND CHRONIC PAIN MANAGEMENT IN SICKLE CELL DISEASE: OUTCOMES OF AN ENGLISH NATIONAL AUDIT.
por: Lugthart, S, et al.
Publicado: (2022)

P-036: PIEZO1 ACTIVATION AUGMENTS SICKLING PROPENSITY AND THE ADHESIVE PROPERTIES OF SICKLE RED BLOOD CELLS
por: N., CONRAN, et al.
Publicado: (2022)

5613459 PAIN IN YOUTH WITH SICKLE CELL DISEASE AND ASSOCIATION WITH SLEEP
por: Hyppolite, R.H., et al.
Publicado: (2023)

Presepsin (sCD14-ST) as a new diagnostic biomarker of sepsis: development of diagnostic tools using the whole blood
por: Shozushima, T
Publicado: (2011)

Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis in systemic inflammatory response syndrome
por: Shozushima, T, et al.
Publicado: (2011)

P-082: VITAMIN B-6 STATUS AND DIETARY INTAKE AMONG CANADIAN CHILDREN WITH SICKLE CELL DISEASE
por: B., WILLIAMS, et al.
Publicado: (2022)

P-053: SICKLE CELL MANAGEMENT AND INTERNATIONAL COOPERATION
por: I., DEME LY, et al.
Publicado: (2022)

Effect of restoration of 25OHD(3 )status in prolonged critical illness on serum innate immunity parameters LL-37 and sCD163
por: Ingels, CM, et al.
Publicado: (2010)

Drotrecogin alfa (activated): a single-centre experience of 110 patients
por: Fletcher, S, et al.
Publicado: (2010)

P-071: HEMATOLOGICAL PROFILE AND ITS INTERRELATIONSHIPS WITH HEMOGLOBIN SUBTYPES IN SICKLE CELL DISEASE PATIENTS OF CHHATTISGARH
por: H., LAD, et al.
Publicado: (2022)

5596737 RETINOPATHY IN EGYPTIAN PATIENTS WITH SICKLE CELL DISEASE
por: Hassan, T.H., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_77j9td7cisjhkv8vd0p97p2m5d